Global Structural Heart Devices Market Report 2024

The structural heart devices market size has grown strongly in recent years. It will grow from $9.5 billion in 2023 to $10.4 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The historical growth can be attributed to several factors, including the shift towards less invasive surgical techniques, the demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, and growing patient preference for non-surgical or minimally invasive treatment options.

The structural heart devices market size is expected to see strong growth in the next few years. It will grow to $15.06 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends expected in the forecast period encompass increasing adoption of transcatheter valve replacement, ongoing development of innovative devices with advanced materials, growing emphasis on personalized treatment approaches, increasing adoption of hybrid procedures, and integration of remote monitoring and telehealth solutions.

The increasing prevalence of cardiovascular diseases is poised to drive the expansion of the structural heart device market in the foreseeable future. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and blood vessels, such as coronary artery disease, heart attacks, and strokes. The incidence of cardiovascular diseases, which include heart disease and stroke, has been steadily rising worldwide due to factors such as sedentary lifestyles, poor dietary habits, increasing obesity rates, smoking, and aging populations. Structural heart devices play a crucial role in treating cardiovascular diseases by repairing or replacing damaged heart valves, correcting structural defects, and enhancing heart function and patient outcomes. For example, in January 2024, a report by the American Heart Association revealed that cardiovascular disease caused 931,578 deaths in the US, slightly up from 928,741 in 2020. Globally, there were 19.91 million CVD deaths in 2021, compared to 19.05 million in 2020. Hence, the escalating prevalence of cardiovascular diseases is fostering the growth of the structural heart device market.

Leading companies in the structural heart devices market are focusing on developing minimally invasive treatment techniques and devices to improve patient outcomes, shorten recovery periods, and broaden treatment options for structural heart conditions. A notable example is the self-expanding transcatheter aortic valve implantation (TAVI) system, designed to deploy and secure the replacement valve within the native aortic valve anatomy without the need for balloon inflation. For instance, in December 2022, Abbott Laboratories introduced Navitor, the latest-generation transcatheter aortic valve implantation (TAVI) system, in India. Navitor is specifically tailored for individuals with severe aortic stenosis at high or extreme surgical risk and incorporates advancements such as a unique design to prevent valve leakage. This innovation expands Abbott's structural heart transcatheter portfolio, offering both physicians and patients minimally invasive treatment alternatives for heart diseases. Navitor stands out as the sole self-expanding TAVI system with intra-annular leaflets and large frame cells, facilitating improved access to coronary arteries for potential future interventions in coronary artery disease (CAD). Additionally, this new design enhances hemodynamics, optimizing blood flow.

In February 2022, Genesis MedTech Group completed the acquisition of JC Medical (JCM) for an undisclosed sum. This strategic move allows Genesis to augment its product portfolio by including J-Valve, a minimally invasive transcatheter aortic valve replacement (TAVR) device designed for both aortic regurgitation and stenosis patients. JC Medical (JCM) is a US-based company specializing in the manufacture of structural heart devices.

Major companies operating in the structural heart devices market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Bracco Group, LivaNova PLC, Meril Life Sciences Pvt. Ltd., CryoLife Inc., Braile Biomédica, TTK Healthcare Limited, Direct Flow Medical Inc., JenaValve Technology Inc., Micro Interventional Devices Inc., CardioKinetix Inc., Xeltis AG, Ancora Heart Inc., JOMDD Inc., Valcare Medical, BioStable Science & Engineering Inc., Comed B.V., Transcatheter Technologies GmbH, Navilyst Medical Inc.

North America was the largest region in the structural heart devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural heart devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Structural heart devices are specialized medical implants or tools tailored for treating various structural defects or abnormalities affecting the heart. They are utilized to repair or replace damaged heart structures, such as valves or septa, thereby restoring normal heart functions and enhancing patient outcomes.

The primary types of structural heart devices include heart valve devices, annuloplasty rings, occluders, and delivery systems. Heart valve devices are medical tools crafted to repair or replace damaged heart valves, ensuring proper blood flow through the heart. These procedures encompass replacement procedures, repair procedures for indications such as atrial septal defect, patent foramen ovale, ventricular septal defect, aortic valve stenosis, and others, catering to age group categories including pediatrics and adults.

The structural heart devices market research report is one of a series of new reports that provides structural heart devices market statistics, including structural heart devices industry global market size, regional shares, competitors with a structural heart devices market share, detailed structural heart devices market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart devices industry. This structural heart devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The structural heart devices market consists of sales of paravalvular leak closure devices, endovascular stents, and percutaneous mitral valve replacement. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.